tetano
Editor, Senior Moderator
Sci Rep
. 2024 Jun 28;14(1):14926.
doi: 10.1038/s41598-024-65489-0. SARS-CoV-2 antigenemia and RNAemia in association with disease severity in patients with COVID-19
Dong-Min Kim[SUP] #[/SUP][SUP] 1 [/SUP], Merlin Jayalal Lawrence Panchali[SUP] 2 [/SUP], Choon-Mee Kim[SUP] #[/SUP][SUP] 3 [/SUP], Da-Yeon Lee[SUP] 2 [/SUP], Jun-Won Seo[SUP] 2 [/SUP], Da Young Kim[SUP] 2 [/SUP], Na Ra Yun[SUP] 2 [/SUP]
Affiliations
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, causes a spectrum of symptoms ranging from mild upper to severe lower respiratory tract infections. However, the dynamics of nucleocapsid (N) protein antigenemia and RNAemia are not fully understood. We conducted a cohort study involving 117 patients with clinically confirmed COVID-19, focusing on the kinetics of antigenemia and RNAemia and their association with various clinical characteristics. The patients had a median age of 66.0 years (52.0-79.0 years), with a gender distribution of 46.2% male and 53.8% female. Antigenemia reached 100% in fatal cases during the first week after admission. The sensitivity/specificity of antigenemia for diagnosis were 64.7%/73.0% at admission, 69.1%/100% in Week 1, and 66.3%/100% in Week 2. Additionally, the rates of antigenemia in asymptomatic patients were 27.3% upon admission and 22.0% in Week 1, respectively; however, no antigenemia was in samples collected in Week 2. Viral RNAemia was not detected in asymptomatic patients, but RNAemia viral loads were elevated in fatal cases. Kaplan-Meier survival curves demonstrated a higher mortality rate when antigenemia concentrations were elevated in the follow-up samples (P = 0.005). Our study provides a comprehensive analysis of the kinetics of viral N-protein antigenemia and RNAemia according to disease severity and clinical classification. Our findings suggest that highest concentrations of antigenemia in fatal cases occur in the first week after admission, indicating that early elevated antigenemia may serve as a marker of mortality risk.
Keywords: Antigenemia; COVID-19; Correlation; Mortality; RNAemia; SARS-CoV-2.
. 2024 Jun 28;14(1):14926.
doi: 10.1038/s41598-024-65489-0. SARS-CoV-2 antigenemia and RNAemia in association with disease severity in patients with COVID-19
Dong-Min Kim[SUP] #[/SUP][SUP] 1 [/SUP], Merlin Jayalal Lawrence Panchali[SUP] 2 [/SUP], Choon-Mee Kim[SUP] #[/SUP][SUP] 3 [/SUP], Da-Yeon Lee[SUP] 2 [/SUP], Jun-Won Seo[SUP] 2 [/SUP], Da Young Kim[SUP] 2 [/SUP], Na Ra Yun[SUP] 2 [/SUP]
Affiliations
- PMID: 38942808
- PMCID: PMC11213952
- DOI: 10.1038/s41598-024-65489-0
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, causes a spectrum of symptoms ranging from mild upper to severe lower respiratory tract infections. However, the dynamics of nucleocapsid (N) protein antigenemia and RNAemia are not fully understood. We conducted a cohort study involving 117 patients with clinically confirmed COVID-19, focusing on the kinetics of antigenemia and RNAemia and their association with various clinical characteristics. The patients had a median age of 66.0 years (52.0-79.0 years), with a gender distribution of 46.2% male and 53.8% female. Antigenemia reached 100% in fatal cases during the first week after admission. The sensitivity/specificity of antigenemia for diagnosis were 64.7%/73.0% at admission, 69.1%/100% in Week 1, and 66.3%/100% in Week 2. Additionally, the rates of antigenemia in asymptomatic patients were 27.3% upon admission and 22.0% in Week 1, respectively; however, no antigenemia was in samples collected in Week 2. Viral RNAemia was not detected in asymptomatic patients, but RNAemia viral loads were elevated in fatal cases. Kaplan-Meier survival curves demonstrated a higher mortality rate when antigenemia concentrations were elevated in the follow-up samples (P = 0.005). Our study provides a comprehensive analysis of the kinetics of viral N-protein antigenemia and RNAemia according to disease severity and clinical classification. Our findings suggest that highest concentrations of antigenemia in fatal cases occur in the first week after admission, indicating that early elevated antigenemia may serve as a marker of mortality risk.
Keywords: Antigenemia; COVID-19; Correlation; Mortality; RNAemia; SARS-CoV-2.